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Methods: 24 skeletally mature New Zealand White rabbits un-
derwent anterior cruciate ligament transection. 6 additional sham
operated animals were used as controls. 10 days after the
surgery the transected animals received an intraarticular injec-
tion of CD-RAP encapsulated in liposomes or liposomes alone
as vehicle control. Three different dose levels of CD-RAP were
tested. Thereafter the animals were injected every 10 days until
the end of the 9-week treatment period. The animals were anal-
ysed macroscopically, radiologically, and histologically. To score
the radiological and histological data, the Kellgren and a modified
Mankin score, respectively, were used.
Results: CD-RAP treatment resulted in reduced osteophyte for-
mation and reduced joint space narrowing. This effect was signif-
icant as shown by the radiological scoring There was a trend to-
wards middle and high dose CD-RAP being more efficacious than
the low dose group but this was not statistically significant. The
histological evaluation by the modified Mankin score, which eval-
uated cartilage structure, cells, matrix (safranin-O), and tidemark
integrity, confirmed the radiological results. The average scores
for sham, vehicle, and treatments groups (low, mid and high dose
CD-RAP) were 1.12±1.19, 7.28±2.19, 7.22±2.69, 4.08±0.8,
4.47±1.93. Both middle and high dose CD-RAP groups showed
a significant improvement over the vehicle group. Looking at the
individual parameters, CD-RAP appeared to impact structural
integrity as well as matrix content.
Conclusions: These data suggest that treatment with the carti-
lage specific protein CD-RAP may be a new therapeutic option
for osteoarthritis patients. Next steps will include the long-term
evaluation of liposome-encapsulated CD-RAP in a large animal
model.
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Purpose: Osteoarthritis is characterized by the progressive de-
struction of articular cartilage. Damage to the collagen network
is often considered irreversible, whereas proteoglycan loss is
reversible. Understanding mechanisms of repair of the collagen
network is therefore key for functional repair of cartilage. The
present study was designed to test whether collagen synthesis
and subsequent crosslinking could be influenced such that a
functional collagen network is formed.
Methods: Bovine articular chondrocytes were cultured in algi-
nate beads for 5 weeks in the presence or absence of the lysyl
oxidase inhibitor BAPN (0.25 mM) followed by 5 weeks without
BAPN (+/- or -/-). Collagen deposition and amout of crosslinks
(HPLC) and gene expression of collagen type 1 and 2 and SOX9
(RT-QPCR) were measured. Susceptibility of the extracellular
matrix to in vitro degradation by MMP-1 was examined after 70
days of culture by overnight incubating 4 alginate beads with
100nM MMP-1. Alginate constructs of 3 mm thick and 6 mm in
diameter were used to determine the equilibrium modulus and
de secant modulus by unconfined compression. Here, an extra
control was added to examine the effect of no crosslinks after 10
weeks of culture with BAPN (+/+).
Results: Complete inhibition of collagen crosslinking for 5 weeks
by BAPN increased the collagen deposition 1.8 times, with a
concomitant increase in tissue stiffness (the equilibrium mod-
ulus increased from 451 Pa to 879 Pa), despite the absence
of crosslinks in the BAPN condition. When after 10 weeks the
amount of collagen is further increased, crosslinks also seem to
be important in improving the stiffness of the matrix. From week 8
onwards, i.e. 3 weeks after removal of the crosslink inhibitor, the
crosslinks returned approaching the level of the control condition
at week 10. With equal amount of crosslinks (-/- and +/-) the
equilibrium modulus is higher when more collagen was present.
However, the total absence of collagen crosslinks together with
more collagen resulted in a lower secant modulus in the +/+ con-
dition, indicating a higher permeability of the matrix. Incubation
of 10-week-old beads in buffer with collagenase MMP-1, lead
to a 2.5 fold increase of collagen release in the supernatant in
the condition without crosslinks (+/+) than in the two conditions
with crosslinks (-/- and +/-). SOX9 expression was not influenced
by addition of BAPN whereas the COL2/COL1 ratio was higher,
indicating that inhibition of crosslinks results in more collagen
without affecting chondrocyte phenotype significantly.
Conclusions: Modulation of the amount of crosslinking and
subsequently collagen deposition, during cartilage tissue regen-
eration has an effect on the functional properties of the construct.
After 5 weeks, more collagen alone led to an increase of stiffness
of the matrix. However, when more collagen was deposited after
10 weeks, crosslinks were also needed to improve matrix stiff-
ness. The quality of the matrix indicated by MMP-1 degradation
susceptibility is not influenced by the transient crosslink inhibi-
tion. These data suggest that modulation of the collagen network
may be a feasible approach to induce cartilage regeneration.
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Purpose: Osteoarthritis is the most prevalent chronic human
disease characterised by a deterioration of cartilage. Despite
its important socio-economical impact, there is, until now, no
satisfactory way to treat the disease. Symptomatic treatment
with antalgics or anti-inflammatory drugs does not stop the
progression of cartilage degeneration, and often presents side-
effects, which limit their chronic use. Our goal is to design new
therapeutic approaches, keeping in mind that cartilage is one of
the rare human tissues which is unable to regenerate. The loss
of matrix components, especially glycosaminoglycans (GAG), is
an early event of cartilage damage.
Methods: An innovative strategy of cartilage bioengineering con-
sists in overexpression by gene transfer, of glycosyltransferases
able to stimulate the anabolic activity of chondrocytes, in or-
der to promote cartilage repair. In that context, the research of
our group is mainly devoted to the identification, cloning and
structural characterisation of key-glycosyltransferases involved
in the biosynthesis of GAG of the cartilage matrix. The work
has been especially focused on the human galactose β 1,3-
glucuronosyltransferase-I (GlcAT-I) which is involved in the final
step of the biosynthesis of the common GAG-protein tetrasac-
charidic linkage sequence, GlcA β1-3Gal β1-3Gal β1-4Xyl-O-.
Results: We have shown that any variation of the GlcAT-I activity
in chondrocytes or cartilage explants, either upon overexpres-
sion, or, in contrast, by repression with antisense RNA, could
increase, or decrease the GAG content in cartilage, respec-
tively. Interestingly, overexpression of this enzyme was able to
completely counteract the proinflammatory cytokine, interleukine
1β-induced depletion of GAG. The neosynthesised GAG were
qualitatively similar to those present in the original cartilage ma-
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trix. This study opens up promising therapeutic avenues based
on gene transfer encoding selected glycosyltransferases.
On a complementary way, we have performed a structural inves-
tigation of the human recombinant GlcAT-I upon expression the
methyltrophic yeast Pichia pastoris. This study allowed to define
the molecular basis of the recognition of the donor and acceptor
substrates of the enzyme. We also determined the critical role of
the modification of the tetrasaccharidic sequence by sulfatation
of Gal residues on the regulation of the activity of GlcAT-I. Finally,
the importance of the other glycosyltransferases involved in the
construction of the tetrasaccharidic sequence is also examined.
Altogether, this study will provide the rational basis for the design
of original glycomimetics able to stimulate GAG biosynthesis in
cartilage.
Conclusions: Glycosyltransferases, especially GlcAT-I, are
promising protein targets for the development of new therapies
for osteoarthritis based on the repair of the GAG components of
cartilage.
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Purpose: Cartilage is avascular and lacks the ability to mobilize
repair cells; thus tissue damage is cumulative. Tissue engineered
cartilage repair may delay or prevent prosthetic replacement and
restore mobility. Mass transport is a major challenge in cartilage
tissue-engineering. Previous studies show that mesenchymal
stem cell (MSC)-based constructs develop a shell of differenti-
ated material surrounding a viable but undifferentiated core. This
suggests that a) penetration of one or more substrates required
for differentiation is limited, or b) more generally, that the differen-
tiation process transiently increases the metabolic requirements
of the cells. The purpose of this study is to understand the na-
ture and time course of the mass transport limitations during the
maturation of tissue engineered constructs.
Methods: We combined in vitro and in silico approaches to un-
derstand the metabolic needs of the cells during chondrogenic
differentiation. Constructs were made from 107 1st passage hu-
man MSCs that were seeded onto collagen-GAG porous scaf-
folds and exposed to a chondrogenic medium in a custom-built
bioreactor. We assessed mass transport within the construct us-
ing dextran tracers of 3, 10 and 70 kDa MW at various time-points
during differentiation. We modelled momentum and mass trans-
port using a finite element analysis software package. A detailed
3-dimensional geometric rendering, Fickian diffusion and Navier-
Stokes equations and Michaelis-Menten oxygen consumption
kinetics were used in the model. Consumption rate estimates
were obtained either from the existing literature or were com-
puted from measurements made using a purpose-built oxygen
consumption cell.
Results: We created a 3-dimensional computer model of our
custom-built bioreactor system and the growing cartilage con-
struct. Diffusion experiments, using image analysis data fitted
to a diffusion model, were used to derive estimates of diffusivi-
ties of 3, 10, and 70 kDa molecular weight fluorescent dextran
tracers through the constructs. The estimated diffusivities in the
constructs were 2-3 orders of magnitude lower than that in water
(0.3-2 vs. 50-240 μm2/sec). The diffusivities also depended on
the molecular weight of the tracer and on the maturity of the
construct; two-week old constructs had the lowest diffusivities.
Mass transport modelling carried out using experimentally de-
termined diffusivities shows that large chondrogenic molecules,
such as TGF-β1, do not reach useful concentrations in the in-
terior of the construct even over a week. In parallel, the initially
high oxygen needs of MSCs decrease during their differentiation
to chondrocytes.
Conclusions: We have developed a model that defines mass
transport through the construct under a variety of culture con-
ditions and will predict the effects of design modifications to
the bioreactor system. Modelling results suggest a limiting role
for substrate mass transport in large-scale cartilage implants.
Specifically, large signalling molecules diffuse slowly into the
constructs resulting in an undifferentiated cartilage shell. Fu-
ture studies will define the dynamics of cell differentiation, and
nutrient-dependent cell division/death. These strategies will ulti-
mately lead to the development of clinically useful tissue engi-
neered cartilage constructs.
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Purpose: Common strategies in the treatment of OA do not
address most of the underlying pathomechanisms. Several bi-
ologically based, local therapies are either in clinical use or in
development. A new therapy based on the intra-articular injec-
tion of autologous conditioned serum (ACS) has shown clinical
benefits in animal and human studies.In the present study, the
clinical efficacy and safety of intra-articular injections of ACS
were compared to intra-articular hyaluronan (HA) and saline in
patients with confirmed knee OA.
Methods: ACS is generated by incubating venous blood with
medical grade glass beads. Peripheral blood leukocytes produce
elevated amounts of endogenous anti-inflammatory cytokines,
such as interleukin-1 receptor antagonist (IL-1Ra), that are re-
covered in the serum(1).
In a prospective, randomized, patient- and observer-blind, saline-
controlled trial with three parallel groups, 399 patients with knee
OA were included with the intention to treat (ITT-) analysis.
Efficacy was assessed by patient-administered outcome instru-
ments (WOMAC, VAS, SF-8, GPA) after 7, 13 and 26 weeks. The
frequency and severity of adverse events were used as safety
parameters.
Results: In all treatment groups, intra-articular injections pro-
duced a significant reduction in WOMAC-scores and weight-
bearing pain (VAS), as well as an improvement in the health-
related quality of life. However, the positive therapeutic responses
to ACS were stronger compared to other treatment modalities.
The superiority of ACS to both HA and saline was statistically sig-
nificant for all outcome measures and all time points. The mean
improvement for patients treated with HA and saline was half
that than in the ACS-group (p<0.001). No significant differences
between HA treatment and saline-injections (p>0,05, at all time
points and all outcome measures) were recorded. Frequency of
adverse advents (AE) was comparable in the ACS- and saline-
group (p>0,05), whereas there were significantly more AE in the
HA-group (p<0,05 for the comparison with ACS and saline).
Conclusions: Patients with OA of the knee treated with intra-
articular injections of ACS showed significantly better clinical
improvement during 26 weeks of observation compared to pa-
tients injected with HA or saline. The results demonstrate that
ACS is effective and well tolerated for treating chronic, idiopathic
OA of the knee. So far, the efficacy of ACS is defined through
improvement in clinical signs and symptoms, particularly pain. It
remains to be determined whether there are disease-modifying,
chondroprotective, or even chondroregenerative, sequelae.
